The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study

PURPOSE: Pamiparib is an investigational, selective, oral poly(ADP-ribose) polymerase 1/2 (PARP1/2) inhibitor that has demonstrated PARP–DNA complex trapping and CNS penetration in preclinical models, as well as preliminary anti-tumor activity in early-phase clinical studies. We investigated whether...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Chemother Pharmacol
Главные авторы: Mu, Song, Lin, Chester, Skrzypczyk-Ostaszewicz, Anna, Bulat, Iurie, Maglakelidze, Marina, Skarbova, Viera, Andreu-Vieyra, Claudia, Sahasranaman, Srikumar
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Berlin Heidelberg 2021
Предметы:
Original Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8149352/
https://ncbi.nlm.nih.gov/pubmed/33772633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-021-04253-x
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы